Debate resumed on amendment No. 4: In page 14, between lines 23 and 24, to insert the following:“(3) The Board shall, in determining an application under subsection (2), have regard to the desirability with respect to efficacy and safety of refusing to add medicinal product in the anti-epileptic drug class, used in the treatment of persons with epilepsy for the purpose of preventing seizures, to the List of Interchangeable Medicinal Products.”.- (Deputy Caoimhghín Ó Caoláin).

See this item in context